Overview of Interventional Radiology Treatment Options

Opinion
Video

Providing the interventional radiologist perspective, Harris Chengazi, MD, gives an overview of available treatment strategies.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
3 experts in this video
Related Content
MEV01 trial results show that the test achieved an 86% early-stage sensitivity and 88% specificity in surveillance of HCC among patients with cirrhosis.

FDA Grants EvoLiver Biopsy Test Breakthrough Device Designation for HCC

Roman Fabbricatore
April 23rd 2025
Article

MEV01 trial results show that the test achieved an 86% early-stage sensitivity and 88% specificity in surveillance of HCC among patients with cirrhosis.

Govindarajan Narayanan, MD, speaks to the potential time-saving advantages of using the Epione robot for microwave ablation, cryoablation, and other surgical strategies in patients with liver cancer and other tumors.

Adapting to a Robotic Workstation for Image-Guided Liver Cancer Surgery

Govindarajan Narayanan, MD
December 4th 2023
Podcast

Govindarajan Narayanan, MD, speaks to the potential time-saving advantages of using the Epione robot for microwave ablation, cryoablation, and other surgical strategies in patients with liver cancer and other tumors.

Most recently, the FDA accepted a second NDA for camrelizumab/rivoceranib as a treatment for patients with unresectable HCC in October 2024.

FDA Issues Second Camrelizumab/Rivoceranib CRL in Hepatocellular Carcinoma

Roman Fabbricatore;Russ Conroy
March 21st 2025
Article

The complete response letter for camrelizumab/rivoceranib for patients with advanced HCC did not specify what deficiencies regulators found.

FDA Grants Fast Track Designation to Amezalpat Combination in HCC

FDA Grants Fast Track Designation to Amezalpat Combination in HCC

Tim Cortese
February 11th 2025
Article

Amezalpat plus atezolizumab and bevacizumab achieved a 6-month increase for OS compared with atezolizumab and bevacizumab alone in patients with HCC.

Findings from the CheckMate 9DW trial support the CHMP’s recommendation for approving nivolumab/ipilimumab for those with unresectable HCC.

Nivolumab Combo Earns Positive CHMP Opinion in Advanced Liver Cancer

Russ Conroy
February 1st 2025
Article

Findings from the CheckMate 9DW trial support the CHMP’s recommendation for approving nivolumab/ipilimumab for those with unresectable HCC.

Results from a phase 2 trial revealed serplulimab plus HLX04 elicited promising antitumor activity in patients with advanced hepatocellular carcinoma.

First-Line Serplulimab Plus HLX04 Shows Manageable Safety in Advanced HCC

Roman Fabbricatore
January 30th 2025
Article

Results from a phase 2 trial revealed serplulimab plus HLX04 elicited promising antitumor activity in patients with advanced hepatocellular carcinoma.